Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O’Shaughnessy J, Miller VA, Ross JS, Ali SM. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Annals Of Oncology 2017, 28: 2866-2873. PMID: 28945887, PMCID: PMC5834148, DOI: 10.1093/annonc/mdx490.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive metastatic breast cancerMetastatic breast cancerBreast cancerGenomic profilingGenomic alterationsEstrogen receptor-positive breast cancerMetastatic breast cancer managementReceptor-positive breast cancerTumor DNACo-occurring genomic alterationsMetastatic tissue biopsiesTissue samplesRoutine clinical careBreast cancer managementCourse of diseasePeripheral blood samplesMetastatic tumor tissueMetastatic diseaseFemale patientsInvasive alternativeCtDNA fractionCancer managementClinical careBlood samplesPatientsGenomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
Pusztai L, Chung J, Young L, Schrock A, Hartmaier R, Frampton G, Gay L, Stephens P, Miller V, Ali S, Ross J, Vahdat L, O'Shaughnessy J. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC). Journal Of Clinical Oncology 2017, 35: 1016-1016. DOI: 10.1200/jco.2017.35.15_suppl.1016.Peer-Reviewed Original ResearchAromatase inhibitor therapyMetastatic breast cancerGenomic profilingCommon genomic alterationsGenomic alterationsTreatment informationTreatment of MBCCo-occurring genomic alterationsConcurrent genomic alterationsPrior chemotherapyInhibitor therapyD538GBreast cancerKinase fusionsTherapeutic approachesClinical careClinical decision